Key Events This Week
1 June: Q4 FY26 results reveal plunging profitability despite revenue growth
3 June: Valuation upgraded to very attractive amid challenging returns
5 June: Week closes at Rs.12.50, down 2.72% for the week
Jun 29, 01:10 PM
BSE+NSE Vol: 1465

Deccan Health Care Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 18 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 June 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.
Read full news article
1 June: Q4 FY26 results reveal plunging profitability despite revenue growth
3 June: Valuation upgraded to very attractive amid challenging returns
5 June: Week closes at Rs.12.50, down 2.72% for the week

Deccan Health Care Ltd has witnessed a significant shift in its valuation parameters, moving from an attractive to a very attractive price range, driven by a marked decline in its price-to-earnings and price-to-book value ratios. This repositioning comes amid a challenging market backdrop and a micro-cap status that continues to weigh on investor sentiment despite recent positive price movements.
Read full news articleDeccan Health Care Ltd's latest financial results for Q4 FY26 reveal a complex operational landscape characterized by notable revenue growth juxtaposed against significant profitability challenges. The company reported a net sales figure of ₹20.98 crores, reflecting a quarter-on-quarter growth of 20.64%, which is a positive development compared to the previous quarter's decline. However, this revenue increase did not translate into improved profitability, as net profit fell sharply by 67.00% to ₹0.33 crores from ₹1.00 crore in Q3 FY26. The operating margin also contracted considerably, dropping from 9.95% in Q3 to 4.24% in Q4, indicating operational difficulties that may stem from either cost pressures or aggressive pricing strategies aimed at driving sales volume. Similarly, the PAT margin experienced a decline from 5.75% to 1.57%, further underscoring the strain on profitability despite the uptick in rev...
Read full news article
Deccan Health Care Limited, a micro-cap healthcare products company specialising in nutraceutical, cosmeceutical and ayurveda products, reported a challenging Q4 FY26 with net profit declining 67.00% quarter-on-quarter to ₹0.33 crores despite revenue growing 20.64% to ₹20.98 crores. The ₹32.00 crore market capitalisation company saw its stock trade at ₹12.80, down 43.36% over the past year and significantly underperforming both the Sensex and its healthcare services sector peers.
Read full news article
Deccan Health Care Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 18 May 2026, driven primarily by a shift in technical indicators despite persistent fundamental challenges. The healthcare services micro-cap, with a current market price of ₹12.33, continues to underperform the broader market but shows signs of stabilisation in its technical trend, prompting a reassessment of its outlook.
Read full news article
Deccan Health Care Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 12 May 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite some positive quarterly financial results and rising promoter confidence, the stock’s overall outlook has worsened due to bearish technical trends, underwhelming long-term returns, and valuation concerns within the healthcare services sector.
Read full news article
Deccan Health Care Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 29 Apr 2026, driven primarily by a shift in technical indicators despite persistent fundamental challenges. The healthcare services micro-cap, with a market capitalisation classified as micro-cap and a current Mojo Score of 34.0, has demonstrated mixed signals across quality, valuation, financial trends, and technical parameters, prompting a nuanced reassessment by analysts.
Read full news article
Deccan Health Care Ltd, a micro-cap player in the Healthcare Services sector, has seen its investment rating downgraded from Sell to Strong Sell as of 23 April 2026. This revision reflects deteriorating technical indicators, persistent underperformance against benchmarks, and weak long-term fundamental metrics despite some recent positive financial results and rising promoter confidence.
Read full news articleResignation of Independent Director
Intimation
Cessation of Chief Financial Officer and Key Managerial Personnel of the Company.
No Upcoming Board Meetings
No Dividend history available
No Splits history available
No Bonus history available
No Rights history available